SCHEMBL9828922

SCHEMBL9828922

Cc1cc(NC(=O)Nc2ccccc2)ccn1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 2/20 0.69
SMARCA4 P51532 2/20 0.69
TAAR1 Q96RJ0 2/20 0.61
KMT2A Q03164 6/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
PKM P14618 1/20 0.58
TP53 P04637 2/20 0.57
TSHR P16473 2/20 0.57
EPHX1 P07099 1/20 0.57
EPHX2 P34913 1/20 0.57
CDK9 P50750 1/20 0.57
CLK4 Q9HAZ1 1/20 0.57
NPC1 O15118 6/20 0.56
RAB9A P51151 6/20 0.56
HTT P42858 2/20 0.56
ATM Q13315 1/20 0.56
KDR P35968 2/20 0.55
MEN1 O00255 4/20 0.54
ADORA3 P0DMS8 1/20 0.54
PIM1 P11309 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25820900 0.90 SMARCA2 (0.61) SMARCA2SMARCA4TAAR1KMT2ASMN1; SMN2
SCHEMBL1493028 0.84 PSEN1 (0.68) CNR1MAPK1PSEN1PSEN2APH1B
SCHEMBL15880685 0.84 SMARCA2 (0.65) SMARCA2SMARCA4KMT2AMEN1SORT1
SCHEMBL24010292 0.82 KMT2A (0.61) SMARCA2SMARCA4TAAR1KMT2ASMN1; SMN2
SCHEMBL22125195 0.82 SMARCA2 (1.00) SMARCA2SMARCA4KMT2ASMN1; SMN2PKM
SCHEMBL3989785 0.82 JAK2 (0.60) SMARCA2SMARCA4KMT2ASMN1; SMN2NPC1
SCHEMBL11366678 0.81 TAAR1 (0.62) SMARCA2SMARCA4TAAR1KMT2ASMN1; SMN2
SCHEMBL17785026 0.81 SMARCA2 (0.67) SMARCA2SMARCA4KMT2ASMN1; SMN2PKM
SCHEMBL10344917 0.80 TAAR1 (0.61) SMARCA2SMARCA4TAAR1KMT2ASMN1; SMN2
SCHEMBL11376239 0.80 TAAR1 (0.61) SMARCA2SMARCA4TAAR1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383331-A1 COMPOSITIONS AND METHODS FOR LARGE-SCALE IN VITRO PLANT BIOCULTURE BOOSHOOT LLC (US) 2020-12-10 US disclosed
WO-2019165172-A1 FORCHLORFENURON MIXTURES AND USES THEREOF VALENT BIOSCIENCES LLC (US) 2019-08-29 WO disclosed
WO-2013016198-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR MICROPROPAGATION OF PLANTS BOOSHOOT LLC (US) 2013-01-31 WO disclosed
US-20120180964-A1 COMPOSITIONS AND METHODS FOR BAMBOO PULPING The Red Triangle, LLC (US) 2012-07-19 US disclosed
WO-2012097380-A1 COMPOSITIONS AND METHODS FOR BAMBOO PULPING The Red Triangle, LLC (US) 2012-07-19 WO disclosed
EP-0279433-B1 PLANTS RESISTANT TO CUCUMBER MOSAIC VIRUS INFECTION Takeda Chemical Industries, Ltd. (JP) 1991-10-23 EP disclosed
EP-0138983-B1 N-PHENYL-N'-(PYRIDINYL-N-OXIDE)UREA PLANT REGULATORS FMC Corporation (US) 1989-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383331-A1 COMPOSITIONS AND METHODS FOR LARGE-SCALE IN VITRO PLANT BIOCULTURE MYB, MYCBP, PIM1 SMARCA2 1904/4885SMARCA4 2061/4885TAAR1 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.